Related references
Note: Only part of the references are listed.Round robin test on quantification of amyloid-beta 1-42 in cerebrospinal fluid by mass spectrometry
Josef Pannee et al.
ALZHEIMERS & DEMENTIA (2016)
Value of cerebrospinal fluid -synuclein species as biomarker in Parkinson's diagnosis and prognosis
Lucilla Parnetti et al.
BIOMARKERS IN MEDICINE (2016)
Synaptic failure and α-synuclein
Laura Calo et al.
MOVEMENT DISORDERS (2016)
Increased CSF neurogranin concentration is specific to Alzheimer disease
Henrietta Wellington et al.
NEUROLOGY (2016)
Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Hlin Kvartsberg et al.
ALZHEIMERS & DEMENTIA (2015)
Non-motor signs in Parkinson's disease: a review
Renato P. Munhoz et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2015)
Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders
Zheng-Yu Wang et al.
INTERNATIONAL PSYCHOGERIATRICS (2015)
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
N. K. Magdalinou et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies
Davide Chiasserini et al.
MOLECULAR NEURODEGENERATION (2015)
Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
Niels Kruse et al.
NEUROBIOLOGY OF AGING (2015)
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Sebastian Palmqvist et al.
NEUROLOGY (2015)
Amyloid biomarkers in Alzheimer's disease
Kai Blennow et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Julien Dumurgier et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity
Tessandra Stewart et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease
Yaroslau Compta et al.
JOURNAL OF NEUROLOGY (2015)
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Alberto Lleo et al.
NATURE REVIEWS NEUROLOGY (2015)
CSF biomarkers and clinical progression of Parkinson disease
Sara Hall et al.
NEUROLOGY (2015)
Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast
Blagovesta Popova et al.
BIOMOLECULES (2015)
Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels
Sylvie Slaets et al.
ALZHEIMERS & DEMENTIA (2014)
Cerebrospinal Fluid Neurofilament Concentration Reflects Disease Severity in Frontotemporal Degeneration
Carole S. Scherling et al.
ANNALS OF NEUROLOGY (2014)
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease
Karen E. Murphy et al.
BRAIN (2014)
Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid
Andreas Leinenbach et al.
CLINICAL CHEMISTRY (2014)
Genomic and Pharmacogenomic Biomarkers of Parkinson's Disease
Hortensia Alonso-Navarro et al.
CURRENT DRUG METABOLISM (2014)
Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Stephen N. Gomperts
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2014)
Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Takashi Kasai et al.
JOURNAL OF NEUROLOGY (2014)
Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions
Nadia Magdalinou et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Mary J. Savage et al.
JOURNAL OF NEUROSCIENCE (2014)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2014)
CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls
Megan K. Herbert et al.
PARKINSONISM & RELATED DISORDERS (2014)
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
Jan O. Aasly et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Lucilla Parnetti et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42 A Cross-Validation Study Against Amyloid Positron Emission Tomography
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2014)
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Niklas Mattsson et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2013)
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium
Maria C. Carrillo et al.
ALZHEIMERS & DEMENTIA (2013)
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson et al.
ALZHEIMERS & DEMENTIA (2013)
Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue
Kim A. Bruggink et al.
ANALYTICAL BIOCHEMISTRY (2013)
Clinical Chemistry and Laboratory Medicine: an appreciation
Graham H. Beastall et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2013)
Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies
Adrien W. Schmid et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson's Disease
Erika Guerrero et al.
MOLECULAR NEUROBIOLOGY (2013)
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease
Karin D. van Dijk et al.
MOVEMENT DISORDERS (2013)
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Ziv Gan-Or et al.
NEUROLOGY (2013)
SYNAPTIC CHANGES IN ALZHEIMER'S DISEASE AND ITS MODELS
J. Pozueta et al.
NEUROSCIENCE (2013)
Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
Malin Wennstrom et al.
PLOS ONE (2013)
Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease
Mikko Holtta et al.
PLOS ONE (2013)
Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
Tobias Skillback et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Correlation of Specific Amyloid-β Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults
Maureen Handoko et al.
JAMA NEUROLOGY (2013)
Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease
Fuyuki Tateno et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2012)
Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease
Pieter Jelle Visser et al.
ALZHEIMERS & DEMENTIA (2012)
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Matthew E. Gegg et al.
ANNALS OF NEUROLOGY (2012)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall et al.
ARCHIVES OF NEUROLOGY (2012)
Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression
R. Tortelli et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia
Stefan Lehnert et al.
EXPERIMENTAL NEUROLOGY (2012)
Neuropathology of Sporadic Parkinson's Disease: Evaluation and Changes of Concepts
Kurt A. Jellinger
MOVEMENT DISORDERS (2012)
Molecular machines governing exocytosis of synaptic vesicles
Reinhard Jahn et al.
NATURE (2012)
Injury markers predict time to dementia in subjects with MCI and amyloid pathology
Ineke A. van Rossum et al.
NEUROLOGY (2012)
Age and diagnostic performance of Alzheimer disease CSF biomarkers
N. Mattsson et al.
NEUROLOGY (2012)
Phosphorylated α-Synuclein in Parkinson's Disease
Yu Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
Min Shi et al.
ANNALS OF NEUROLOGY (2011)
Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
Joseph R. Mazzulli et al.
CELL (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Cerebrospinal Fluid Tau/α-Synuclein Ratio in Parkinson's Disease and Degenerative Dementias
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2011)
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Tim Bartels et al.
NATURE (2011)
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
William E. Klunk
NEUROBIOLOGY OF AGING (2011)
Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease
James B. Leverenz et al.
PARKINSONISM & RELATED DISORDERS (2011)
Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
Ming Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Ozlem Goker-Alpan et al.
ACTA NEUROPATHOLOGICA (2010)
The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia
Walter J. Schulz-Schaeffer
ACTA NEUROPATHOLOGICA (2010)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Annika Thorsell et al.
BRAIN RESEARCH (2010)
High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Hiroaki Fukumoto et al.
FASEB JOURNAL (2010)
A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation
Elisa A. Waxman et al.
JOURNAL OF NEUROCHEMISTRY (2010)
CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
Guido Alves et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Biomarkers in Alzheimer's disease drug development
Kaj Blennow
NATURE MEDICINE (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
A. Siderowf et al.
NEUROLOGY (2010)
Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders
Radu Constantinescu et al.
PARKINSONISM & RELATED DISORDERS (2010)
Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Carol Man Gao et al.
PLOS ONE (2010)
Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects
Leslie M. Shaw et al.
ANNALS OF NEUROLOGY (2009)
Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type
Barbara J. Snider et al.
ARCHIVES OF NEUROLOGY (2009)
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Niklas Mattsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
Pieter Jelle Visser et al.
LANCET NEUROLOGY (2009)
Cerebrospinal Tau, Phospho-Tau, and Beta-Amyloid and Neuropsychological Functions in Parkinson's Disease
Yaroslau Compta et al.
MOVEMENT DISORDERS (2009)
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment
Miroslaw Brys et al.
NEUROBIOLOGY OF AGING (2009)
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies
L. Parnetti et al.
NEUROBIOLOGY OF DISEASE (2009)
Cerebrospinal fluid α-synuclein in neurodegenerative disorders-A marker of synapse loss?
Annika Ohrfelt et al.
NEUROSCIENCE LETTERS (2009)
Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients
Yoshiro Saito et al.
NEUROSCIENCE LETTERS (2009)
Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
Laura Parkkinen et al.
ACTA NEUROPATHOLOGICA (2008)
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Lucilla Parnetti et al.
BIOLOGICAL PSYCHIATRY (2008)
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
Tianhong Pan et al.
BRAIN (2008)
Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity:: Prevention by systemic passive immunization
Igor Klyubin et al.
JOURNAL OF NEUROSCIENCE (2008)
Lysosomal storage disease 1 - Phenotype, diagnosis, and treatment of Gaucher's disease
Gregory A. Grabowski
LANCET (2008)
Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia
Kurt A. Jellinger
NEURODEGENERATIVE DISEASES (2008)
CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment -: A follow-up study
G. Li et al.
NEUROLOGY (2007)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease
Chiara Balducci et al.
MOVEMENT DISORDERS (2007)
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
S. W. Scheff et al.
NEUROLOGY (2007)
CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease
W. Farid Abdo et al.
NEUROBIOLOGY OF AGING (2007)
Prediction of Alzheimer's disease using the CSF A beta 42/A beta 40 ratio in patients with mild cognitive impairment
Oskar Hansson et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's Disease
A. W. Michell et al.
CELL TRANSPLANTATION (2007)
Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism
Tetyana Duka et al.
FASEB JOURNAL (2006)
Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease
Takahiko Tokuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease
Masaaki Waragai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases
J Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein
V Dorval et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
E Portelius et al.
JOURNAL OF PROTEOME RESEARCH (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan et al.
ANNALS OF NEUROLOGY (2006)
Cognitive status correlates with neuropathologic stage in Parkinson disease
H Braak et al.
NEUROLOGY (2005)
Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction
PH Reddy et al.
JOURNAL OF ALZHEIMERS DISEASE (2005)
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
DG Georganopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Ubiquitination of α-synuclein
T Nonaka et al.
BIOCHEMISTRY (2005)
Core biological marker candidates of Alzheimer's disease -: perspectives for diagnosis, prediction of outcome and reflection of biological activity
H Hampel et al.
JOURNAL OF NEURAL TRANSMISSION (2004)
Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway
HJ Lee et al.
JOURNAL OF NEUROSCIENCE (2004)
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease
R Bandopadhyay et al.
BRAIN (2004)
Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling
KP Huang et al.
JOURNAL OF NEUROSCIENCE (2004)
CSF markers for incipient Alzheimer's disease
K Blennow et al.
LANCET NEUROLOGY (2003)
α-synuclein is degraded by both autophagy and the proteasome
JL Webb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
Attenuation of protein kinase C and cAMP-dependent protein kinase signal transduction in the neurogranin knockout mouse
JF Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Practice parameter: Diagnosis of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
DS Knopman et al.
NEUROLOGY (2001)
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
E Masliah et al.
NEUROLOGY (2001)
Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
BI Giasson et al.
SCIENCE (2000)
Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review
Evita Evangelia Christou et al.
SEMINARS IN OPHTHALMOLOGY